Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch [Seeking Alpha]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Seeking Alpha
A U.S. FDA BLA filing of RP-L102 for the treatment of patients with Falconi Anemia is expected in the 1st half of 2024. PDUFA date of June 30th of 2024 to determine if Kresladi should be approved for the treatment of patients with leukocyte adhesion deficiency-I. Rocket Pharmaceuticals had $407.5 million in cash as of December 31st of 2023; Enough cash to fund its operations into 2026. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Rocket Pharmaceuticals, Inc. NASDAQ: RCKT ) is an ideal biotech to keep an eye on this year. That's because it has made advancements on several fronts in terms of possible regulatory approvals for its gene therapies. In particular, just today, it noted that the European Medicines Agency [EMA] just accepted its regulatory application of Lentiviral [LV] RP-L102 for the treatment of patients with Fanconi Anemia [FA]. This is good news, as it starts the review process so that it could re
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $39.00 price target on the stock.MarketBeat
RCKT
Earnings
- 2/26/24 - Beat
RCKT
Sec Filings
- 4/24/24 - Form 4
- 4/22/24 - Form 144
- 4/17/24 - Form PRE
- RCKT's page on the SEC website